Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01360853 · ClinicalTrials.gov registry record · Phase 3
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Traws Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT01360853 is a Phase 3 study that has completed, run by Traws Pharma. The registered enrollment target is 160 participants.
The verdict
NCT01360853, a Phase 3 study, has completed, sponsored by Traws Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine alone? There are two parts to this study. In the first part of the study, patients with metastatic pancreatic cancer who have received no prior chemotherapy for this disease will be assigned by chance either to the group that will be treated with both Gemcitabine and ON 01910.Na (about 100 patients will be in this group) or, to the group that will be treated with Gemcitabine only (about 50 patients will be in this group). How long patients survive in the 2 groups will be compared. If it looks like there is no difference between the groups, the study will stop. If it looks like patients in the group that were treated with both Gemcitabine and ON 01910.Na survive longer, the study will continue into a second part where more patients will be treated in order to confirm and better understand the findings of the first part of the study.
Interventions
- DRUG Gemcitabine
- DRUG ON 01910.Na
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01360853
The ClinicalTrials.gov registry entry for NCT01360853 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Traws Pharma, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01360853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01360853 about?
NCT01360853 is a clinical study titled "Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer". The question being asked in this study is: Will patients with advanced pancreatic cancer live significantly longer if they are treated with a combination of Gemcitabine and ON 01910.Na than if they are treated with Gemcitabine alone? There are two parts to this study. In the first part of the study,...
What is the current status of trial NCT01360853?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2011-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01360853?
The interventions under investigation include: Gemcitabine (DRUG), ON 01910.Na (DRUG).
Who is sponsoring clinical trial NCT01360853?
This trial is sponsored by Traws Pharma, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.